AnaptysBio (ANAB)
(Delayed Data from NSDQ)
$35.71 USD
+2.01 (5.96%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $35.72 +0.01 (0.03%) 6:04 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for AnaptysBio, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -163.62 | -128.72 | -57.80 | -19.93 | -97.34 |
Depreciation/Amortization & Depletion | -8.15 | -0.17 | 2.58 | 1.02 | 0.51 |
Net Change from Assets/Liabilities | -0.32 | 6.84 | -7.49 | -6.77 | 16.85 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 51.29 | 48.46 | 16.78 | 11.53 | 10.45 |
Net Cash From Operating Activities | -120.80 | -73.59 | -45.92 | -14.16 | -69.52 |
Property & Equipment | -0.81 | -0.36 | -1.35 | -0.57 | -0.81 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 145.56 | -394.49 | 40.19 | 95.04 | 132.24 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 144.75 | -394.85 | 38.84 | 94.48 | 131.43 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -47.53 | 11.83 | 2.55 | 0.50 | 3.01 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | -1.38 | -7.50 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -11.77 | 32.19 | 249.75 | 0.00 | 0.00 |
Net Cash from Financing Activities | -59.30 | 44.02 | 252.30 | -0.88 | -4.49 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -35.34 | -424.42 | 245.21 | 79.44 | 57.42 |
Cash at Beginning of Period | 71.31 | 495.73 | 250.52 | 171.08 | 113.66 |
Cash at End of Period | 35.97 | 71.31 | 495.73 | 250.52 | 171.08 |
Diluted Net EPS | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 |
Fiscal Year End for AnaptysBio, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -43.94 | -163.62 | -121.41 | -84.10 |
Depreciation/Amortization & Depletion | NA | -2.36 | -8.15 | -5.60 | -3.19 |
Net Change from Assets/Liabilities | NA | -7.40 | -0.32 | 2.33 | 11.34 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 16.45 | 51.29 | 38.22 | 25.98 |
Net Cash From Operating Activities | NA | -37.25 | -120.80 | -86.45 | -49.98 |
Property & Equipment | NA | -0.03 | -0.81 | -0.53 | -0.37 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 68.64 | 145.56 | 96.10 | 65.31 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 68.62 | 144.75 | 95.58 | 64.94 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.81 | -47.53 | -47.79 | -47.95 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -14.44 | -11.77 | -6.35 | -3.11 |
Net Cash from Financing Activities | NA | -13.63 | -59.30 | -54.14 | -51.07 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 17.73 | -35.34 | -45.01 | -36.10 |
Cash at Beginning of Period | NA | 35.97 | 71.31 | 71.31 | 71.31 |
Cash at End of Period | NA | 53.70 | 35.97 | 26.30 | 35.21 |
Diluted Net EPS | NA | -1.64 | -1.59 | -1.41 | -1.50 |